Mission

Establishing tomorrow's standard of care

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Clinical trials

Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.

More about clinical trials

Highlights

Drug development

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX…

Drug development

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Agenda

Let's meet

ECCMID 2020

April 18 - 21, 2020 Paris, France Discover

Your task is not to foresee the future, but to enable it.

Antoine de St-Exupéry

History

For 40 years, we have been driven by the same commitment: bringing innovative solutions to patients

Our story began in 1979 when Dr. Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, he decided to establish Debiopharm, a company dedicating to in-licensing innovative compounds and developing them into medicines for out-licensing. Having launched this unique business model with a staff of only 2 people, today, Debiopharm’s 420 employees are now active in a variety of roles within drug development, drug manufacturing and investment in digital health and smart data start-ups.

Together with his son Thierry Mauvernay, they were able to build team of dedicated professionals with a broad range of expertise. Debiopharm is now a group of three companies active un drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and digital health investment (Debiopharm Innovation Fund).